Successful Treatment of Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Immunodeficiency With Extended Nirmatrelvir/Ritonavir: Case Series
Madison Breeden, Samuel L Aitken, Ji Hoon Baang, Misty Gravelin, Daniel Kaul, Adam S. Lauring, Lindsay A Petty, Kevin Gregg
Abstract
Immunocompromised patients with B-cell deficiencies are at risk for prolonged symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We describe 4 patients treated for B-cell malignancies with B-cell-depleting therapies who developed persistent SARS-CoV-2 infection and had resolution of symptoms following an extended course of nirmatrelvir/ritonavir.
Topics & Concepts
MedicineRitonavirCoronavirusRespiratory systemRespiratory infectionInternal medicineImmunologyVirologyCoronavirus disease 2019 (COVID-19)Human immunodeficiency virus (HIV)Viral loadDiseaseAntiretroviral therapyInfectious disease (medical specialty)COVID-19 Clinical Research StudiesImmunodeficiency and Autoimmune DisordersSARS-CoV-2 and COVID-19 Research